Supernus Pharma (SUPN) Tops Q4 EPS by 5c, Revenues Miss; Offers FY21 Revenue Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. AMD
3. PLTR
4. CRWD
5. DOX
6. VRTX
7. CHKP
8. ON
9. HNGE
10. INSP

Go back to Supernus Pharma (SUPN) Tops Q4 EPS by 5c, Revenues Miss; Offers FY21 Revenue Guidance Below Consensus

Supernus Announces Fourth Quarter and Full Year 2020 Financial Results

February 25, 2021 4:00 PM EST

Full year 2020 total revenues of $520.4 million, a 32% increase compared to 2019Full year 2020 operating earnings of $173.7 million, a 17% increase compared to 2019SPN-812 NDA assigned an early April 2021 PDUFA datePositive results from Phase III study for SPN-812 in adults with ADHD announced in December 2020Full year 2021 total revenues guidance of $550 million to $580 million

ROCKVILLE, Md., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported financial results for the... More